Clinical Trial Update: Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing safety and efficacy of tafamidis in transthyretin cardiomyopathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Tafamidis (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy | Phase 3 | Status: COMPLETED | Results posted: 2019-04-03